Full text is available at the source.
Abstract
Alzheimer's disease (AD) is the leading cause of dementia in older individuals.
- AD represents a significant clinical and socioeconomic challenge.
- Current anti-amyloid therapies successfully reduce biomarker burden but may not provide optimal effectiveness or safety.
- Emerging evidence suggests metabolic dysfunction and brain insulin resistance may play a role in AD development.
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are being considered as potential therapies that could modify the disease.
Simplified